Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
Abstract Monoclonal antibodies directed against interleukin (IL)‐5, such as mepolizumab and benralizumab, are an effective and established treatment for severe eosinophilic asthma. Here, we present a patient with eosinophilic asthma with a partial clinical response to mepolizumab initially, as measu...
Main Authors: | Alistair Cook, John Harrington, Jodie L. Simpson, Peter Wark |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-05-01
|
Series: | Respirology Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/rcr2.742 |
Similar Items
-
Efectividad de mepolizumab y benralizumab en una cohorte de pacientes con asma grave eosinofílico en vida real
by: María José Espinosa de los Monteros Garde, et al.
Published: (2021-04-01) -
Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
by: S. K. Zyryanov, et al.
Published: (2020-12-01) -
Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
by: Arian Ghassemian, et al.
Published: (2021-01-01) -
Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
by: Koki Fujii, et al.
Published: (2020-11-01) -
Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
by: Drick N, et al.
Published: (2020-11-01)